Unión Europea - español - EMA (European Medicines Agency)

bayer animal health gmbh - el florfenicol, terbinafine hydrochloride, mometasone furoate - otologicals, corticosteroides y antiinfectives en combinación - perros - para el tratamiento de la otitis externa canina o las exacerbaciones agudas de la otitis media recurrente causada por infecciones mixtas de cepas susceptibles de bacterias sensibles al florfenicol (staphylococcus pseudintermedius) y hongos sensibles a la terbinafina (malassezia pachydermatis).

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Unión Europea - español - EMA (European Medicines Agency)

orion corporation - ropinirole hydrochloride - agentes dopaminérgicos, los agonistas de la dopamina - perros - la inducción de vómitos en los perros.

Unión Europea - español - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - clorhidrato de doxorrubicina - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agentes antineoplásicos - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Unión Europea - español - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - imágenes de radionúclidos - radiofármacos terapéuticos - endolucinbeta es un precursor radiofarmacéutico y no está destinado para uso directo en pacientes. se debe usar solo para el radiomarcaje de moléculas transportadoras que se hayan desarrollado y autorizado específicamente para el radiomarcaje con cloruro de lutecio (177lu)..

Unión Europea - español - EMA (European Medicines Agency)

i.d.b. radiopharmacy b.v. - lutetium (177lu) chloride - imágenes de radionúclidos - radiofármacos terapéuticos - lumark es un precursor radiofarmacéutico. no está destinado para uso directo en pacientes. este medicamento debe usarse solo para el radiomarcaje de moléculas portadoras, que se han desarrollado y autorizado específicamente para el radiomarcaje con este radionúclido..

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

johnson and johnson, s.a. - difenhidramina hidrocloruro - excipientes: - antihistamÍnicos para uso sistÉmico - aminoalquil éteres - difenhidramina

Unión Europea - español - EMA (European Medicines Agency)

eckert ziegler radiopharma gmbh - yttrium (90y) chloride - imágenes de radionúclidos - radiofármacos de diagnóstico - se utilizará únicamente para el radiomarcaje de moléculas portadoras, que se desarrollaron específicamente y autorizaron para el radiomarcaje con este radionúclido. radiofármaco precursor - no destinados para uso directo en los pacientes.

Unión Europea - español - EMA (European Medicines Agency)

virbac s.a. - clomipramine hydrochloride - psicoanalépticos - perros - as an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.

Unión Europea - español - EMA (European Medicines Agency)

orion corporation - dexmedetomidine hydrochloride - psicolépticos - dogs; cats - procedimientos y exámenes no invasivos, de leve a moderadamente dolorosos, que requieren restricción, sedación y analgesia en perros y gatos. premedicación en gatos antes de la inducción y el mantenimiento de anestesia general con ketamina. sedación profunda y analgesia en perros en uso concomitante con butorfanol para procedimientos quirúrgicos médicos y menores. premedicación en perros antes de la inducción y mantenimiento de la anestesia general.